Drug development
The development of biotechnologically produced drugs has made it possible to treat diseases at their cause, to do this more efficiently and with fewer side effects, or even to cure diseases. This is the focus of five biotechnology companies on Campus Berlin-Buch.
The spectrum of their drug development includes highly specific cancer antibodies (Glycotope GmbH), novel treatments targeting the cause of heart failure (Berlin Cures GmbH) or atrial fibrillation (OMEICOS Therapeutics GmbH), extremely effective antibiotics (MerLion Pharmaceuticals) and RNAi-based therapeutics for systemic cancers that can selectively regulate disease-related genes (Silence Therapeutics). Here, T-Knife, a spin-off from the Charité and the Max Delbrück Center, is developing one of the first T cell receptor gene therapies in Germany.
News innovation
Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
Eckert & Ziegler (ISIN DE0005659700) has entered a Master Service Agreement with Archeus Technologies (Archeus), a company developing multiple differentiated radiopharmaceutical therapies, for contrac...
more ...Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation.
The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) resolved on June 18, 2025, to increase the share capital using company funds by € 42,343,864 to € 63,515,796.
more ...Eckert & Ziegler: Outstanding Training Quality Once Again Awarded
Eckert & Ziegler SE (ISIN DE0005659700) has been recognized by the Berlin Chamber of Industry and Commerce (IHK) for the exceptional quality of its training program for the fourth time in a row.
more ...Events Campus
09.09.2025, 09:00
From Target to Market - The BBA Biotech & Pharma Summer School
The 4-day intensive course provides a comprehensive overview of the entire drug development process in biotechnology and in the pharmaceutical industry – from the idea to the market.
more ...18.09.2025, 17:00
Talk im Cube: IP Strategies in Biotechnology
We are excited to continue the Talks in the Cube with a further expert discussion focused on Strategies for Intellectual Property Rights in Biotechnology.
more ...23.09.2025, 09:00
GMP Biotech Summer School
Good Manufacturing Practice (GMP) Basic Course Biotechnology (English) & ATMPs
more ...
